

QUANTIFY
RESEARCH

Burden of hepatitis C in Europe – the case of France and Romania

2015-06-05

Gustaf Ortsäter

*The hepatitis C landscape is
changing rapidly.*


What does the future hold?

How do policy decisions affect the future?


Objectives

Burden encompasses both clinical outcomes, such as quality of life and mortality, and economical ones

1. Describe the current burden of hepatitis C in Europe
2. Assess the impact of increased treatment



The model



Analyses conducted

- Scenario A
 - Patients are treated with current standard of care* and treatment levels are kept constant throughout the model


- Scenario B
 - Patients are treated with current standard of care* but treatment levels are increased between 2014 and 2018 after which treatment levels are returned to current levels

- Scenario C
 - Patients are treated with drugs of increased efficacy and treatment levels are increased between 2014 and 2018 after which treatment levels are returned to current levels

*Peg-interferon + ribavirin + protease inhibitor in genotype 1 and
Peg-interferon + ribavirin in other genotypes in France (average SVR ~57%).
Peg-interferon and ribavirin in all genotypes in Romania (average SVR ~33%).


Economic burden of HCV in Romania

Scenario A




Health care costs

Romania




Total costs

Romania




Liver cancer

Romania




Economic burden of hepatitis C in France

Scenario A




Health care costs

France




Total costs

France



Liver cancer

France



Conclusions

- Burden of hepatitis C is substantial, regardless of country settings
- Despite decreased prevalence, total health care cost is projected to increase under current conditions
- Policy decisions today will impact long-term budgets and health outcomes
- This study shows the value of treatment investments
 - Economic value
 - Decreased morbidity and mortality

Tale of two countries

- Case of Romania shows
 - high cost of suboptimal treatment in short and long term
 - increased coverage must be combined with better treatment
- Case of France shows
 - recent positive trends can be reinforced with treatment investments
 - investment can be both in increased coverage and better treatments
- Optimal treatment strategies may differ between countries
 - Current generic model be extended and adapted to more countries

Hepatitis C impacts people's lives and society's costs greatly.

The treatment landscape changes rapidly. This should be reflected in policy.

About Quantify Research

Quantify Research is an experienced partner in health economics, outcomes research, real-world evidence, and market access. Our goal is to continuously deliver high quality services, combining our scientific and quantitative skills with a solution-oriented mindset and business focus.

We have our roots in academia with a broad technical competence in value strategy, modeling, evidence generation, biostatistics, study design and analysis.

Through extensive experience within both the governmental and private sectors, we have acquired a dynamic and efficient work model, putting emphasis on communication and finding tailored solutions to fit our clients' needs.

Address: Hantverkargatan 8, Stockholm
Web: www.quantifyresearch.com

**QUANTIFY
RESEARCH**